Fiche centre
CTI Clinical Research Center
Cincinnati — United States
Essais liés8clinical trials
VilleCincinnatilocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT03235479
Essais cliniques associés
8| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Elismetrep (K-304) 2 mg | Migraine | Phase 2 | NCT06848075 | A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine | COMPLETED |
| Atogepant | Migraine | Phase 3 | NCT03777059 | 12-Week Placebo-controlled Study of Atogepant for the Preventive Treatment of Migraine in Participants With Episodic Migraine | COMPLETED |
| Atogepant | Migraine | Phase 3 | NCT03939312 | Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine | COMPLETED |
| Rimegepant | Migraine | Phase 3 | NCT03235479 | Safety and Efficacy Study in Adult Subjects With Acute Migraines | COMPLETED |
| Dihydroergotamine | Migraine | Phase 3 | NCT03901482 | EMERGE — A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine | COMPLETED |
| Dihydroergotamine | Migraine | Phase 3 | NCT04406649 | ASCEND — A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine | COMPLETED |
| Dihydroergotamine | Migraine | Phase 3 | NCT04940390 | SUMMIT — A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine | COMPLETED |
| Rimegepant | Migraine | Phase 2/3 | NCT03266588 | Open Label Safety Study in Acute Treatment of Migraine | COMPLETED |